{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,4]],"date-time":"2022-11-04T05:07:46Z","timestamp":1667538466401},"reference-count":46,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2020,7,30]]},"DOI":"10.1536\/ihj.19-654","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T22:05:27Z","timestamp":1595023527000},"page":"673-684","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of Durable-Polymer- and Biodegradable-Polymer-Based Newer-Generation Drug-Eluting Stents in Patients with Acute Myocardial Infarction and Prediabetes After Successful Percutaneous Coronary Intervention"],"prefix":"10.1536","volume":"61","author":[{"given":"Yong Hoon","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kangwon National University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ae-Young","family":"Her","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kangwon National University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Ho","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Cardiovascular Center, Chonnam National University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byeong-Keuk","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-Jin","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seunghwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Inje University College of Medicine, Haeundae Paik Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chul-Min","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Sun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Guk","family":"Ko","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghoon","family":"Choi","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myeong-Ki","family":"Hong","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangsoo","family":"Jang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Authors\/Task Force Members, Ryd\u00e9n L, Grant PJ, <i>et al<\/i>. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013; 34: 3035-87.","DOI":"10.1093\/eurheartj\/eht108"},{"key":"2","unstructured":"2. Wahab NN, Cowden EA, Pearce NJ, <i>et al<\/i>. Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol 2002; 40: 1748-54."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Stranders I, Diamant M, van Gelder RE, <i>et al<\/i>. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. Arch Intern Med 2004; 164: 982-8.","DOI":"10.1001\/archinte.164.9.982"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Naber CK, Mehta RH, J\u00fcnger C, <i>et al<\/i>. Impact of admission blood glucose on outcomes of nondiabetic patients with acute ST-elevation myocardial infarction (from the German Acute Coronary Syndromes [ACOS] Registry). Am J Cardiol 2009; 103: 583-7.","DOI":"10.1016\/j.amjcard.2008.11.005"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Bolk J, van der Ploeg T, Cornel JH, Arnold AE, Sepers J, Umans VA. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol 2001; 79: 207-14.","DOI":"10.1016\/S0167-5273(01)00422-3"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Dal Canto E, Ceriello A, Ryd\u00e9n L, <i>et al<\/i>. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol 2019; 26: 25-32.","DOI":"10.1177\/2047487319878371"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. BARI 2D Study Group, Frye RL, August P, <i>et al<\/i>. A randomized trial of therapies for Type 2 diabetes and coronary artery disease. N Engl J Med 2009; 360: 2503-15.","DOI":"10.1056\/NEJMoa0805796"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Dangas GD, Farkouh ME, Sleeper LA, <i>et al<\/i>. Long-term outcome of PCI versus CABG in insulin and non-insulin-treated diabetic patients: results from the FREEDOM Trial. J Am Coll Cardiol 2014; 64: 1189-97.","DOI":"10.1016\/j.jacc.2014.06.1182"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ 2016; 355: i5953.","DOI":"10.1136\/bmj.i5953"},{"key":"10","doi-asserted-by":"crossref","first-page":"e1049","DOI":"10.4244\/EIJ-D-17-01067","volume":"14","year":"2018","unstructured":"10. Kok MM, von Birgelen C, Sattar N, <i>et al<\/i>. Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population. EuroIntervention 2018; 14: e1049-56.","journal-title":"EuroIntervention","ISSN":"http:\/\/id.crossref.org\/issn\/1774-024X","issn-type":"print"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Ali MK, Bullard KM, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014. Lancet Diabetes Endocrinol 2018; 6: 392-403.","DOI":"10.1016\/S2213-8587(18)30027-5"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Costa RA, Abizaid A, Mehran R, <i>et al<\/i>. Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions: 4- and 12-month angiographic follow-up and final 5-year clinical outcomes of the prospective, multicenter BioFreedom FIM clinical trial. JACC Cardiovasc Interv 2016; 9: 51-64.","DOI":"10.1016\/j.jcin.2015.09.008"},{"key":"13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.4244\/EIJ-D-17-00734","volume":"14","year":"2018","unstructured":"13. Iglesias JF, Muller O, Zaugg S, <i>et al<\/i>. A comparison of an ultrathin-strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the BIOSTEMI trial. EuroIntervention 2018; 14: 692-9.","journal-title":"EuroIntervention","ISSN":"http:\/\/id.crossref.org\/issn\/1774-024X","issn-type":"print"},{"key":"14","doi-asserted-by":"publisher","unstructured":"14. Kim YH, Her AY, Jeong MH, <i>et al<\/i>. One-year clinical outcomes between biodegradable-polymer-coated biolimus-eluting stent and durable-polymer-coated drug-eluting stents in STEMI patients with multivessel coronary artery disease undergoing culprit-only or multivessel PCI. Atherosclerosis 2019; 284: 102-9.","DOI":"10.1016\/j.atherosclerosis.2019.02.022"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Kaiser C, Galatius S, Jeger R, <i>et al<\/i>. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitats Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation 2015; 131: 74-81.","DOI":"10.1161\/CIRCULATIONAHA.114.013520"},{"key":"16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.4244\/EIJV11I3A53","volume":"11","year":"2015","unstructured":"16. Vlachojannis GJ, Smits PC, Hofma SH, <i>et al<\/i>. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial. EuroIntervention 2015; 11: 272-9.","journal-title":"EuroIntervention","ISSN":"http:\/\/id.crossref.org\/issn\/1774-024X","issn-type":"print"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. I\u00f1iguez A, Chevalier B, Richardt G, <i>et al<\/i>. Comparison of long-term clinical outcomes in multivessel coronary artery disease patients treated either with bioresoarbable polymer sirolimus-eluting stent or permanent polymer everolimus-eluting stent: 5-year results of the Century II randomized clinical trial. Catheter Cardiovasc Interv 2019; 95: 175-84.","DOI":"10.1002\/ccd.28224"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Korea Acute Myocardial Infarction Registry (KAMIR) Investigators, Lee KH, Jeong MH, <i>et al<\/i>. Gender differences of success rate of percutaneous coronary intervention and short term cardiac events in Korea Acute Myocardial Infarction Registry. Int J Cardiol 2008; 130: 227-34.","DOI":"10.1016\/j.ijcard.2007.08.044"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Grech ED. ABC of interventional cardiology: percutaneous coronary intervention. II: The procedure. BMJ 2003; 326: 1137-40.","DOI":"10.1136\/bmj.326.7399.1137"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. American Diabetes Association. Standards of medical care in diabetes--2010. Diabetes Care 2010; 33 (Suppl 1): S11-61.","DOI":"10.2337\/dc10-S011"},{"key":"21","first-page":"e362","volume":"127","year":"2013","unstructured":"21. O&apos;Gara PT, Kushner FG, Ascheim DD, <i>et al<\/i>. 2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127: e362-425.","journal-title":"Circulation","ISSN":"http:\/\/id.crossref.org\/issn\/0009-7322","issn-type":"print"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Ibanez B, James S, Agewall S, <i>et al<\/i>. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2018; 39: 119-77.","DOI":"10.1093\/eurheartj\/ehx393"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Amsterdam EA, Wenger NK, Brindis RG, <i>et al<\/i>. 2014 AHA\/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 130: e344-426.","DOI":"10.1161\/CIR.0000000000000134"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Roffi M, Patrono C, Collet JP, <i>et al<\/i>. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315.","DOI":"10.1093\/eurheartj\/ehv320"},{"key":"25","unstructured":"25. Amsterdam EA, Wenger NK, Brindis RG, <i>et al<\/i>. 2014 AHA\/ACC Guideline for the Management of Patients with non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 64: e139-228."},{"key":"26","doi-asserted-by":"publisher","unstructured":"26. Kim YH, Her AY, Jeong MH, <i>et al<\/i>. A comparison between statin with ACE inhibitor or ARB therapy in STEMI patients who underwent successful PCI with drug-eluting stents. Atherosclerosis 2019; 289: 109-17.","DOI":"10.1016\/j.atherosclerosis.2019.08.018"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kim YH, Her AY, Jeong MH, <i>et al<\/i>. Comparison between beta-blockers with angiotensin-converting enzyme inhibitors and beta-blockers with angiotensin II Type I receptor blockers in ST-segment elevation myocardial infarction after successful percutaneous coronary intervention with drug-eluting stents. Cardiovasc Drugs Ther 2019; 33: 55-67.","DOI":"10.1007\/s10557-018-6841-7"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Bundhun PK, Wu ZJ, Chen MH. Is there any significant difference in stent thrombosis between sirolimus and paclitaxel eluting stents?: A systematic review and meta-analysis of randomized controlled trials. Med (Baltim) 2016; 95: e2651.","DOI":"10.1097\/MD.0000000000002651"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Planer D, Witzenbichler B, Guagliumi G, <i>et al<\/i>. Impact of hyperglycemia in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention: the HORIZONS-AMI trial. Int J Cardiol 2013; 167: 2572-9.","DOI":"10.1016\/j.ijcard.2012.06.054"},{"key":"30","doi-asserted-by":"publisher","unstructured":"30. Esposito K, Nappo F, Marfella R, <i>et al<\/i>. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002; 106: 2067-72.","DOI":"10.1161\/01.CIR.0000034509.14906.AE"},{"key":"31","doi-asserted-by":"publisher","unstructured":"31. Williams SB, Goldfine AB, Timimi FK, <i>et al<\/i>. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97: 1695-701.","DOI":"10.1161\/01.CIR.97.17.1695"},{"key":"32","doi-asserted-by":"publisher","unstructured":"32. Stegenga ME, van der Crabben SN, Levi M, <i>et al<\/i>. Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 2006; 55: 1807-12.","DOI":"10.2337\/db05-1543"},{"key":"33","doi-asserted-by":"publisher","unstructured":"33. Oswald GA, Corcoran S, Yudkin JS. Prevalence and risks of hyperglycaemia and undiagnosed diabetes in patients with acute myocardial infarction. Lancet 1984; 1: 1264-7.","DOI":"10.1016\/S0140-6736(84)92447-4"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Kowalczyk J, Mazurek M, Zielinska T, <i>et al<\/i>. Prognostic significance of HbA1c in patients with AMI treated invasively and newly detected glucose abnormalities. Eur J Prev Cardiol 2015; 22: 798-806.","DOI":"10.1177\/2047487314527850"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Stone GW, Rizvi A, Newman W, <i>et al<\/i>. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010; 362: 1663-74.","DOI":"10.1056\/NEJMoa0910496"},{"key":"36","unstructured":"36. Stefanini GG, Windecker S. Stent thrombosis: no longer an issue with newer-generation drug-eluting stents? Circ Cardiovasc Interv 2012; 5: 332-5."},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Yang X, Liu Q, Yuan L, Wang H, Xie Q. Comparison of limus-eluting and paclitaxel-eluting stents for coronary intervention in patients with chronic kidney disease. Int Heart J 2018; 59: 1202-10.","DOI":"10.1536\/ihj.17-583"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Naidu SS, Krucoff MW, Rutledge DR, <i>et al<\/i>. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE v United States study. JACC Cardiovasc Interv 2012; 5: 626-35.","DOI":"10.1016\/j.jcin.2012.02.014"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39. Park SJ, Kang SJ, Virmani R, Nakano M, Ueda Y. In-stent neoatherosclerosis: a final common pathway of late stent failure. J Am Coll Cardiol 2012; 59: 2051-7.","DOI":"10.1016\/j.jacc.2011.10.909"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Bangalore S, Toklu B, Amoroso N, <i>et al<\/i>. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ 2013; 347: f6625.","DOI":"10.1136\/bmj.f6625"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Palmerini T, Biondi-Zoccai G, Della Riva D, <i>et al<\/i>. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol 2014; 63: 299-307.","DOI":"10.1016\/j.jacc.2013.09.061"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Koppara T, Cheng Q, Yahagi K, <i>et al<\/i>. Thrombogenicity and early vascular healing response in metallic biodegradable polymer-based and fully bioabsorbable drug-eluting stents. Circ Cardiovasc Interv 2015; 8: e002427.","DOI":"10.1161\/CIRCINTERVENTIONS.115.002427"},{"key":"43","doi-asserted-by":"publisher","unstructured":"43. Kolandaivelu K, Swaminathan R, Gibson WJ, <i>et al<\/i>. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 2011; 123: 1400-9.","DOI":"10.1161\/CIRCULATIONAHA.110.003210"},{"key":"44","doi-asserted-by":"crossref","first-page":"717","DOI":"10.4244\/EIJV10I6A124","volume":"10","year":"2014","unstructured":"44. Nakazawa G, Shinke T, Ijichi T, <i>et al<\/i>. Comparison of vascular response between durable and biodegradable polymer-based drug-eluting stents in a porcine coronary artery model. EuroIntervention 2014; 10: 717-23.","journal-title":"EuroIntervention","ISSN":"http:\/\/id.crossref.org\/issn\/1774-024X","issn-type":"print"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. El-Hayek G, Bangalore S, Casso Dominguez A, <i>et al<\/i>. Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. JACC Cardiovasc Interv 2017; 10: 462-73.","DOI":"10.1016\/j.jcin.2016.12.002"},{"key":"46","doi-asserted-by":"publisher","unstructured":"46. Nathan DM, Turgeon H, Regan S. Relationship between glycated haemoglobin levels and mean glucose levels over time. Diabetologia 2007; 50: 2239-44.","DOI":"10.1007\/s00125-007-0803-0"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/4\/61_19-654\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T05:39:56Z","timestamp":1667453996000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/61\/4\/61_19-654\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.19-654","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,30]]}}}